A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3

Blood Cells, Molecules, and Diseases

Volumn 50, Issue 2, 2013, Pages 119-130

  Lichtman, Marshall A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Anthracycline antibiotics; Antimetabolites; Chemotherapy; Cytosine arabinoside; Daunorubicin

Indexed keywords

5 THIOGUANINE; CACTINOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DNA; FLOXURIDINE; IDOXURIDINE; MERCAPTOPURINE; METHOTREXATE; MITOGUAZONE; PREDNISONE; RNA; THIOGUANINE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DNA STRUCTURE; DRUG DESIGN; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; HISTORY; HUMAN; HYPOGLYCEMIA; NATIONAL HEALTH ORGANIZATION; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RNA STRUCTURE; THROMBOCYTE TRANSFUSION; UNITED STATES;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; CASE MANAGEMENT; CHILD; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOGS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FORECASTING; FRANCE; HAPLORHINI; HEMATOLOGY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); RATS; REMISSION INDUCTION; UNITED STATES;

EID: 84871989429     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2012.10.005     Document Type: Article

References (92)

1. Hirsch J. An anniversary for cancer chemotherapy. JAMA 2006, 296:1518-1520.
2. (last accessed October 15, 2012). http://www.ysubbarow.info/anti.html.
3. Pearson O.H., Eliel E.P. Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias. JAMA 1950, 144:1349-1353.
4. Rinsky R.A., Smith A.B., Hornung R., Filloon T.G., Young R.J., Okun A.H., Landrigan P.J. Benzene and leukemia. An epidemiologic risk assessment. N. Engl. J. Med. 1987, 316:1044-1050.
5. Johnson G.T., Harbison S.C., McCluskey J.D., Harbison R.D. Characterization of cancer risk from airborne benzene exposure. Regul. Toxicol. Pharmacol. 2009, 55:361-366.
6. Lichtman M.A. Cigarette smoking, cytogenetic abnormalities, and acute myelogenous leukemia. Leukemia 2007, 21:1137-1140.
7. Lichtman M.A. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 2010, 15:1083-1101.
8. Party Working, Research Medical Council; Treatment of acute leukemia in adults: comparison of steroid and mercaptopurine therapy alone and in conjunction. Br. Med. J. 1966, 1:1383-1389.
9. Hersh E.M., Bodey G.P., Nies B.A., Freireich E.J. Causes of death in acute leukemia. JAMA 1965, 193:99-103.
10. Gaydos L.A., Freireich E.J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N. Engl. J. Med. 1962, 266:905-909.
11. Bodey G.P., Nies B.A., Freireich E.J. Multiple organism septicemia in acute leukemia: analysis of 54 episodes. Arch. Intern. Med. 1965, 116:266-272.
12. Dameshek W., Necheles T.F., Finkel H.E., Allen D.M. Therapy of acute leukemia. Blood 1965, 26:220-225.
13. Law L.W. Effects of combinations of antileukemic agents on an acute lymphocytic leukemia in mice. Cancer Res. 1952, 12:871-878.
14. Goldin A., Humphreys S.R., Mantel N., Vendetti J.M. Combined treatment of advanced leukemia (L1210) in mice with amethopterin and 6-mercaptopurine. J. Natl. Cancer Inst. 1956, 17:631-638.
15. Goldin A., Vendetti J.M., Humphreys S.R., Mantel N. Modification of treatment schedules ion the management of advanced mouse leukemia with Amethopterin. J. Nat. Cancer Inst. 1956, 17:203-212.
16. Skipper H.E., Schabel S.J., Wilcox W.S. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother. Rep. 1964, 35:1-111.
17. Furth J., Kahn M.C. The transmission of leukaemia of mice with a single cell. Am. J. Cancer 1937, 31:276-282.
18. Mirand E.A. Legacy and History of Roswell Park Cancer Institute 1898-1998 1998, 9. The Donning Company Publishers, Virginia Beach VA.
19. Kliman B., Peterson R.E. Isotope derivative assay of aldosterone in biological extracts. Fed. Proc. 1958, 17:255a.
20. 14C by human liver. J. Clin. Endocrinol. 1964, 24:638-643.
21. Frei E. Acute leukemia in children. Model for the development of scientific methodology for clinical therapeutic research in cancer. Cancer 1984, 53:2013-2025.
22. Holland J.F., Frei E., Burchenal J.A. Criteria for remission in acute leukemia. Proceedings of the sixth International Congress of the International Society of Hematology, Boston, August 27-September 1, 1956 1958, 213-214. Grune & Stratton edit, New York.
23. Frei E., Holland J.F., Schneiderman M.A., Pinkel D., Selkirk G., Freireich E.J., Silver R.T., Gold G.L., Regelson W. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 1958, 13:1126-1148.
24. Elion G.B., Hitchings G.H. Metabolic basis for the actions of analogs of purines and pyrimidines. Adv. Chemother. 1965, 2:91-177.
25. Avery M.E., Elion Gertrude B. Biographical Memoir 2000, 78:1-4. National Academies Press.
26. D-arabinofuranosyluracil). J. Chem. Soc. 1956, 37:2388-2393.
27. D-arabinofuranosylthymine (spongothymidine). J. Am. Chem. Soc. 1957, 79:2775-2778.
28. Walwick E.R., Roberts W.K., Dekker C.A. Cyclisation During The Phosphorylation Of Uridine And Cytidine By Polyphosphoric Acid - A New Route To The O-2,2'-Cyclonucleosides. Proc. Chem. Soc. (Lond.) 1959, 3:84.
29. Pizer L.I., Cohen S.S. Metabolism of pyrimidine arabinonucleosides and cyclonucleosides in Escherichia coli. J. Biol. Chem. 1960, 235:2387-2392.
30. Schlecta L. Effect of arabinonucleosides on growth and metabolism of E. coli. Fed. Proc. 1961, 20:357a.
31. D-arainofuranosylcytosine hydrochloride. Proc. Soc. Exp. Biol. Med. 1961, 106:350-353.
32. Wodinsky I., Kensler C.J. Activity of cytosine arabinoside (NSC-63878) in a spectrum of rodent tumors. Cancer Chemother. Rep. 1965, 47:65-68.
33. D-arabinofuranosylcytosine hydrochloride on murine neoplasms. Cancer Res. 1964, 24:1285-1293.
34. D-arabinofuranosyl-cytosine as an inhibitor of the growth of leukemic cells. Biochem. Pharmacol. 1962, 11:423-430.
35. Papac R., Creasy W.A., Calabresi P., Welch A.D. Clinical and pharmacological studies with 1-b-D-arabinofuranosylcytosine (cytosine arabinoside). Cancer Res. 1965, 6:50a.
36. Dixon R.L., Adamson R.H. Antitumor activity and pharmacologic disposition of cytosine arabinoside (NSC-63878). Cancer Chemother. Rep. 1965, 48:11-16.
37. Caminier G.W., Smith C.G. Studies on the enzymatic deamination of cytosine arabinoside. I Enzyme distribution and species specificity. Biochem. Pharmacol. 1965, 14:1405-1416.
38. D-arabinofuranosylcytosine hydrochloride. II. Effectiveness against intercerebrally and subcutaneously inoculated leukemic cells. Cancer Res. 1966, 26:1930-1937.
39. Kline I., Venditti J.M., Tyrer D.D., et al. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules. Cancer Res. 1966, 26:853-859.
40. Johnston R.L. Toxicity of U-19, 920A; Confidential report 1960, The Upjohn Company.
41. Talley R.W., Vaitkevicius V.K. Megaloblastosis produced by a cytosine antagonist:1-b-D-arabinofuranosylcytosine. Blood 1963, 21:352-362.
42. Vilter R.W., Horrigan D., Mueller J.F., Jarrold T., Vilter C.F., Hawkins V., Seaman A. Studies on the relationships of vitamin B12, folic acid, thymine, uracil and methyl group donors in persons with pernicious anemia and related megaloblastic anemias. Blood 1950, 5:695-717.
43. Skipper H.E., Schabel F.M., Wilcox W.S. Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother. Rep. 1967, 51:125-165.
44. Freireich E.J., Bodey G.P., Harris J.E., Hart J.S. Therapy for acute granulocytic leukemia. Cancer Res. 1967, 27:2573-2577.
45. Ellison R.R., Holland J.F., Silver R.T., Bernard J., Boiron M. Cytosine arabinoside: a new agent for induction of remission in acute leukemia. Proceedings of the Ninth International Cancer Congress, Tokyo 1966.
46. Ellison R.R., Carey R.W., Holland J.F. Continuous infusion of arabinosyl cytosine in patients with neoplastic disease. J. Clin. Pharm. Ther. 1967, 8:800-809.
47. Bernard J., Boiron M., Jacquillat C., Weil M., Najean Y. Un nouvel agent actif dans traitment des leucemies aigue. Presse Med. 1966, 74:799-802.
48. Ellison R.R., HollandF J.F., Weil M., Jacquillat C., Boiron M., et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968, 32:507-523.
49. Henderson E., Serpick A., Leventhal B., Henry P. Cytosine arabinoside infusions in adult and childhood acute myelocytic leukemia. Cancer Res. 1968, 9:29a.
50. Henderson E.S. Treatment of acute leukemia. Ann. Int. Med. 1968, 69:628-632.
51. Henderson E. Treatment of acute leukemia. Semin. Hematol. 1969, 6:271-318.
52. Hart R.D., Ohnuma T., Holland J.F., Bruckner H. Methyl-GAG in patients with malignant neoplasms: a phase I re-evaluation. Cancer Treat. Rep. 1982, 66:65-71.
53. Waxman Selman Abraham The Nobel Prize Winners. Physiology or Medicine 1944-1969, vol. 2:649-657. Salem Press, Pasadena, CA. F.N. Magill (Ed.).
54. Waksman S.A., Woodruff H.B. Bacteriostatic and bactericidal substances produced by a soil actinomyces. Proc. Soc. Exp. Biol. Med. 1940, 45:609-614.
55. Waksman S.A. The actinomycins and their importance in the treatment of tumors in animals and man. Ann. N. Y. Acad. Sci. 1960, 89:285-485.
56. Brockmann H., Bauer K. Rhodomycin, ein rotes Antibioticum aus Actinomyceten. Naturwissenschaften 1950, 37:492-493.
57. Brockmann H. Anthracyclinone und Anthracycline (rhodomycinone, pyrromycinone und ihre glucoside). Fortschr. Chem. Org. Naturst. 1963, 21:121-182.
58. Dubost M., Ganter P., Maral R., Ninet L., Pinnert S., Preud'homme J., Werner G.-H. Un nouvel antibiotique à propriétés cytostatiques; la rubidomycine. C. R. 1963, 257:1813-1815.
59. Cassinelli G., Orezzi P. La daunomicina - un nuovo antibiotico ad attività citostatica isolamento e proprietà. Giorn. Microbiol. 1963, 11:167-174.
60. Grein A., Spalla C., DiMarco A., Canevazzi G. Descrizione e classificazione di un attinomicete (Streptomyces peucetius sp. nova) produttore di una sostanza ad attività antitumorale: la Daunomicina. Giorn. Microbiol. 1963, 11:109-118.
61. Despois R., Dubost M., Mancy D., Maral R., Ninet L., Pinnert S., Preud'Homme J., Charpentie Y., Belloc A., de Chezelles N., Lunel J., Renaut J. Isolement d'un nouvel antibiotique doué d'activité antitumorale; la rubidomycine (13057 R.P.). Identité de la rubidomyocine et de la daunomycine. Colloque international sur la rubidomycine et la daunomycine. Paris. HÔpital Saint-Louis, 11 Mars 1967. Pathol. Biol. 1967, 15:887-891.
62. Di Marco A., Gaetani M., Dorigotti L., Soldati M., Bellini O. Daunomycin: a new antibiotic with antitumor activity. Cancer Chemother. Rep. 1964, 38:31-38.
63. Calendi E., DiMarco A., Reggiani M., Scarpinato B., Valentini L. On physico-chemical interactions between daunomycin and nucleic acids. Biochim. Biophys. Acta 1965, 103:25-49.
64. Kersten W., Kersten H., Szybalski W. Physicochemical properties of complexes between deoxyribonucleic acid and antibiotics which affect ribonucleic acid synthesis (actinomycin, daunomycin, cinerubin, nogalamycin, chormomycin, mithramycin, and olivomycin). Biochemistry 1966, 5:236-244.
65. Dimarco A., Soldati M., Fioretti A., Dasdia T. Activity of daunomycin, a new antitumor antibiotic, on normal and neoplastic cell growth in vitro. Cancer Chemother. Rep. 1964, 38:39-47.
66. Bernard J., Paul R., Boitron M., Jacquillat C., Maral R. Rubidomycin. Recent results. Cancer Res. 1969, 20:1-181.
67. Jacquillat C., Tanzer J., Boiron M., Najean Y., Weil M., Bernard J. Rubidomycin A new agent active in the treatment of acute lymphoblatic leukemia. Lancet 1966, 2(1966):27-28.
68. Bernard J., Jacquillat C., Boiron M., Najean Y., Seligmann M., Tanzer J., Weil M., Lortholary P. Essai de traitment des leucémies aiguës lymphoblastiques et myéloblastiques par un antibiotique nouveau: La rubidomycine (13 057 RP). Étude de 61 observations. Presse Med. 1967, 75:951-955.
69. Macrez C., Marneffe-Lebrequier H., Ripault J., Clauvel J.-P., Jacquillat C., Weil M. Accidents cardiaques observés au cours des traitments par la rubidomycine. Pathol. Biol. 1967, 15:949-953.
70. Bernard J., Boiron M., Holland J., Jacquillat C., Weil M. Rubidimycin (daunomycin) in the treatment of acute granulocytic leukemia, (A.G.L.). Cancer Res. 1968, 9:5a.
71. Boiron M., Jacquillat C., Weil M., Tanzer J., Levy D., Sultan C., Bernard J. Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet 1969, 1:330-333.
72. Groupe Cooperateur des léucemies et hémotosarcomes Treatment of acute granulocytic leukemias with daunomycin. Eur. J. Cancer 1969, 5:339-342.
73. Carey R.W. Comparative study of cytosine arabinoside (CA) therapy alone and combined with thioguanine (TG) mercaptopurine (MP or daunomycin (DN) in acute myelocytic leukemia (AML). Cancer Res. 1970, 11:15a. for Acute Leukemia Group B.
74. Crowther D., Bateman C.J., Vartan C.P., et al. Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br. Med. J. 1970, 4:513-517.
75. Brincker H. Treatment of acute myeloid leukaemia with cytosine arabinoside and daunomycin in combination. Scand. J. Haematol. 1972, 9:657-664.
76. Gluckman E., Basch A., Varet B., et al. Combination chemotherapy with cytosine arabinoside and rubidomycin in 30 cases of acute granulocytic leukemia. Cancer 1973, 31:487-491.
77. Hoagland H.C., Kyle R. Comparison of intermittent Ara C + cyclophosphamide with Ara C + daunorubicin in induction and maintenance of untreated acute myelocytic leukemia. Minutes of the Acute Leukemia Group B meeting, July 29, 1972 1972, 22.
78. Yates J.W., Wallace J., Ellison R.R., Holland J.F. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute non-lymphocytic leukemia. Cancer Chemother. Rep. 1973, 57:485-488.
79. Rai K.R., Holland J.F., Glidewell O.J., Weinberg V., Brunner K., Obrecht J.P., Preisler H.D., Nawabi I.W., Prager D., Carey R.W., Cooper M.R., Haurani F., Hutchison J.L., Silver R.T., Falkson G., Wiernik P., Hoagland H.C., Bloomfield C.D., James G.W., Gottlieb A., Ramanan S.V., Blom J., Nissen N.I., Bank A., Ellison R.R., Kung F., Henry P., McIntyre O.R., Kaan S.K. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981, 58:1203-1212.
80. Derolf A.R., Kristinsson S.Y., Andersson T.M., Landgren O., Dickman P.W., Björkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009, 113:3666-3672.
81. Greiner U., Ono Y., Hofmann S., Schmitt A., Mehring E., Götz M., Guillaume P., Döhner K., Mytilineos J., Döhner H., Schmitt M. Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. Blood 2012, 120:1282-1289.
82. Anguille S., Willemen Y., Lion E., Smits E.L., Berneman Z.N. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012, 14:647-656.
83. Kadowaki N., Kitawaki T. Recent advance in antigen-specific immunotherapy for acute myeloid leukemia. Clin. Dev. Immunol. 2011, 2011:104926.
84. Becker M.W., Jordan C.T. Leukemia stemness signatures step toward the clinic. Cell Stem Cell 2011, 9:185-186.
85. Rosen D.B., Cordeiro J.A., Cohen A., Lacayo N., Hogge D., Hawtin R.E., Cesano A. Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leuk. Res. 2012, 36:900-904.
86. Lo M.C., Peterson L.F., Yan M., Cong X., Jin R., Shia W.J., Matsuura S., Ahn E.Y., Komeno Y., Ly M., Ommen H.B., Chen I.M., Hokland P., Willman C.L., Ren B., Zhang D.E. Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML. Blood 2012, 120:1473-1484.
87. Lichtman M.A. Interrupting the inhibition of normal hematopoiesis in myelogenous leukemia: a hypothetical approach to therapy. Stem Cells 2000, 18:304-306.
88. Murray M.Y., Rushworth S.A., MacEwan D.J. Micro RNAs as a new therapeutic target towards leukaemia signaling. Cell. Signal. 2012, 24:363-368.
89. Menzin J., Lang K., Earle C.C., Kerney D., Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch. Intern. Med. 2002, 162:1597-1603.
90. C.T. Jordan, Personal communication. University of Rochester Medical Center. September 4, 2012.
91. Lichtman M.A. Battling the hematological malignancies: the 200 years' war. Oncologist 2008, 13:126-138.
92. Sun G.H., Steinberg J.D., Jagsi R.J. The calculus of national medical research policy-The United States versus Asia. N. Engl. J. Med. 2012, 367:687-690.